Molecular magnetic resonance imaging (MRI) holds great promise for diagnosis and therapeutic monitoring in a wide range of diseases. However, the low intrinsic sensitivity of MRI to detect exogenous contrast agents and the lack of biodegradable microprobes have prevented its clinical development. Here, we synthetized a contrast agent for molecular MRI based on a previously unknown mechanism of self-assembly of catechol-coated magnetite nanocrystals into microsized matrix-based particles. The resulting biodegradable microprobes (M3P for microsized matrix-based magnetic particles) carry up to 40,000 times higher amounts of superparamagnetic material than classically used nanoparticles while preserving favorable biocompatibility and excellent water dispersibility. After conjugation to monoclonal antibodies, targeted M3P display high sensitivity and specificity to detect inflammation in vivo in the brain, kidneys, and intestinal mucosa. The high payload of superparamagnetic material, excellent toxicity profile, short circulation half-life, and widespread reactivity of the M3P particles provides a promising platform for clinical translation of immuno-MRI.
Functionalized iron oxide nanoparticles (IONPs) are increasingly being designed as a theranostic nanoplatform combining specific targeting, diagnosis by magnetic resonance imaging (MRI), and multimodal therapy by hyperthermia. The effect of the size and the shape of IONPs is of tremendous importance to develop theranostic nanoobjects displaying efficient MRI contrast agents and hyperthermia agent via the combination of magnetic hyperthermia (MH) and/or photothermia (PTT). Another key parameter is that the amount of accumulation of IONPs in cancerous cells is sufficiently high, which often requires the grafting of specific targeting ligands (TLs). Herein, IONPs with nanoplate and nanocube shapes, which are promising to combine magnetic hyperthermia (MH) and photothermia (PTT), were synthesized by the thermal decomposition method and coated with a designed dendron molecule to ensure their biocompatibility and colloidal stability in suspension. Then, the efficiency of these dendronized IONPs as contrast agents (CAs) for MRI and their ability to heat via MH or PTT were investigated. The 22 nm nanospheres and the 19 nm nanocubes presented the most promising theranostic properties (respectively, r2 = 416 s−1·mM−1, SARMH = 580 W·g−1, SARPTT = 800 W·g−1; and r2 = 407 s−1·mM−1, SARMH = 899 W·g−1, SARPTT = 300 W·g−1). MH experiments have proven that the heating power mainly originates from Brownian relaxation and that SAR values can remain high if IONPs are prealigned with a magnet. This raises hope that heating will maintain efficient even in a confined environment, such as in cells or in tumors. Preliminary in vitro MH and PTT experiments have shown the promising effect of the cubic shaped IONPs, even though the experiments should be repeated with an improved set-up. Finally, the grafting of a specific peptide (P22) as a TL for head and neck cancers (HNCs) has shown the positive impact of the TL to enhance IONP accumulation in cells.
30 January 2023 in International Journal of Pharmaceutics
Iron oxide nanoparticles (IONPs) are increasingly used in the biomedical field. Indeed, they can improve patient diagnosis, as they are excellent T2 contrast agents for magnetic resonance imaging (MRI), and they can be considered a therapeutic and radiosensitizing agent for cancer by influencing the redox balance. However, to achieve specific accumulation of nanoparticles in the tumor, active targeting with specific ligands is required. In this context, we have developed IONPs that would specifically target head and neck cancer (HNC) cells. First, we optimized IONP synthesis and produced dendronized IONPs that were coupled with the targeting ligand cRGD (@D + cRGD IONPs) or peptide 22 (@D + P22 IONPs). The former is a tripeptide with affinity for integrins while the latter is a dodecapeptide analog of GE11, an EGF (epidermal growth factor) derived polypeptide with affinity for EGFR. EGFR is overexpressed in these HNC cells. Next, we highlighted the interest of using @D + P22 IONPs in order to enhance internalization of IONPs in vitro. Furthermore, we evaluated the biodistribution of IONPs in vivo and showed by MRI an immediate T2 contrast in the liver and kidney, whatever the type of IONP. Finally, we developed an in vivo model of mice with FaDu xenografts and showed by MRI a tendency for higher accumulation of @D + P22 IONPs (10.1% decrease of T2 calculated in the tumoral region by measurement) compared to @D IONPs (0.15%) within the tumors. These preliminary results are encouraging and require further investigations, but they suggest the potential interest of using this IONP model for targeting EGFR-positive tumors.
This chapter describes the structure and magnetic properties of iron oxide nanoparticles (IONPs), which are currently being developed for biomedical applications, especially in the case of cancer treatment. Cancer is a major public health issue worldwide, with increasing incidence and mortality rates. According to the Global Cancer Observatory (GLOBOCAN), it is the second leading cause of death globally, after ischemic heart disease; responsible for an estimated 9.6 million deaths in 2018. Early diagnosis is essential for effective treatment and management. Patients with early-stage cancers have a better chance of survival and may require less aggressive treatments, leading to a better quality of life. However, detecting cancer at an early stage is challenging due to the lack of sensitive and specific diagnostic tools. Furthermore, conventional treatments such as chemotherapy and radiation therapy are efficient but show limitations due to the non-specific targeting of cancer cells and potential toxicity to healthy tissues. Therefore, there is a need for the development of both novel diagnostic methods that can accurately detect cancer at an early stage as well as novel therapeutic strategies that are more effective and less toxic. Iron oxide nanoparticles (IONPs) represent an interesting solution, offering implementation of a theranostic approach. Thanks to their magnetic properties, the particles act as contrast agents for magnetic resonance imaging (MRI) but also as therapeutic agents for magnetic hyperthermia (MH) or as drug delivery systems. Here the different ways to synthesize nanoparticles are quickly described, the thermal decomposition method is emphasized as it allows a fine control of the nanoparticles size distribution. Then biological applications of nanoplatforms designed for theranostics will serve as examples to emphasize the interest of these materials.
Conception et validation du ciblage de nanoplateformes théranostiques à base d'oxyde de fer combinant hyperthermie magnétique et/ou photothermie pour le traitement des cancers tête et cou: Pour améliorer le traitement du cancer, il est nécessaire de développer des nanoparticules théranostiques multifonctionnelles capables, en un seul nano-objet, de cibler et de diagnostiquer sélectivement par IRM les tumeurs et de fournir un double traitement thérapeutique par hyperthermie magnétique (HM) et photothermie (PTT). Les nanoparticules d'oxyde de fer superparamagnétiques sont des candidats théranostiques très prometteurs car ce sont des agents de contraste T2 bien connus et déjà commercialisés pour l'IRM et, en jouant sur leur design, il est possible d’augmenter leur efficacité en tant qu’agent de contraste et en tant qu’agent thérapeutique pour l’hyperthermie. En ajustant des paramètres expérimentaux de la synthèse par décomposition thermique, nous avons été capables de synthétiser des nanoparticules d’oxyde de fer de tailles et formes variées. Après leur dendronisation, leur efficacité en tant qu’agents de contraste pour l’IRM et en tant qu’agents chauffants pour les deux thérapies ont été évaluée. Parmi les nanoparticules testées, les nanosphères de 20 – 25 nm de diamètre, ainsi que les nanocubes de 15 - 20 nm de longueur sont les plus prometteurs pour combiner efficacement IRM, MH et PTT. Un autre défi majeur à relever pour avoir une nanoplateforme théranostique efficace est d'augmenter l'internalisation des nanoparticules dans le site tumoral après injection intraveineuse. En effet, elles sont principalement accumulées dans la tumeur par l'effet EPR, et l'internalisation des nanoparticules n'est souvent pas assez élevée pour assurer un diagnostic et une thérapie fiables et efficaces. Ainsi, nous avons développé une stratégie de ciblage dit actif pour cibler les cancers de type tête et cou. Un ligand de ciblage (nommé P22) ciblant le récepteur EGFR surexprimé dans ce type de cancer a été sélectionné et une stratégie pour le coupler et le doser à la surface des nanoparticules a été développée. Des études in vitro et in vivo ont prouvé son efficacité pour augmenter l'internalisation des nanoparticules dans les cellules tumorales.